CHRI invites others who have collected data or developed research tools related to the health impacts of medicinal cannabis to share relevant materials.
Just need to view the repository?
Request Access
Repository Contributors
Characterizing the Epidemiology of Cannabidiol (CBD) Use Among US Adults
Contributed by: Eric C. Leas, PhD, MPH – Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego
CataloguedDataset Summary
This dataset contains de-identified survey data from a nationally sampled, probability-based online survey of U.S. adults conducted by Ipsos Public Affairs on behalf of the University of California San Diego in October–November 2023. Respondents were recruited from Ipsos KnowledgePanel, and the survey was administered in English and Spanish.
The final main survey file includes 2,880 screening respondents, including 1,525 qualified respondents, and 314 variables. Survey measures cover CBD use prevalence and frequency, product type, dose, mode of use, purchase source, purposes for use, health conditions, clinician recommendation, medication substitution and adjunct use, self-reported adverse events, other substance use, awareness and use of derived cannabinoid products including delta-8-THC, CBN, CBG, and HHC, microdosing of cannabis and selected psychedelic substances, self-rated physical and mental health, quality of life, demographics, geographic profile variables, and survey weights.
The dataset is intended to support research on cannabinoid product use, health behaviors, policy environments, and public health implications among U.S. adults.
Related Publications
- Satybaldiyeva N, Yang KH, Kepner W, Ferran K, Leas EC. Prevalence and reasons for using cannabidiol, delta-8 tetrahydrocannabinol, cannabinol, cannabigerol, and hexahydrocannabinol among US adults. Journal of Cannabis Research. 2025;7(1):100. doi:10.1186/s42238-025-00359-8. Full text
- Satybaldiyeva N, Yang KH, Kepner WE, Leas EC. U.S. State Marijuana and Delta-8-Tetrahydrocannabinol Laws and Delta-8-Tetrahydrocannabinol Use. American Journal of Preventive Medicine. 2025;69(6):108026. doi:10.1016/j.amepre.2025.108026. Full text
- Austin EAC, Berghammer L, Ellis SE, Appolon G, Brooks J, Rice NM, Land P, Ping S, Satybaldiyeva N, Grant I, Leas EC. Self-reported use of cannabidiol as a substitute or adjunct for approved medications. Frontiers in Public Health. 2026;14:1720348. doi:10.3389/fpubh.2026.1720348. Full text
- Yang KH, Satybaldiyeva N, Kepner W, Friedman J, Ping S, Leas EC. Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among US Adults. American Journal of Preventive Medicine. 2026;108381. doi:10.1016/j.amepre.2026.108381. Full text
OASIS: Observational Anxiety Study on Inflammation and Stress
Contributed by: University of Colorado Boulder, Institute of Cognitive Science – CU Change
CataloguedDataset Summary
This dataset was collected from 2017–2022 on adults living in the Denver/Boulder area with at least mild anxiety symptoms who were either regular cannabis users or had not used in the past 6 months. Participants were divided into four groups: 1) cannabis users randomly assigned to a THC-dominant product, 2) users randomly assigned to a balanced THC:CBD product, 3) users randomly assigned to a CBD-dominant product, and 4) non-users who served as a comparison group. Data was then collected on participants over the course of 4 weeks as they consumed their assigned legal market flower ad libitum, with measures collected on demographics, psychiatric symptoms, substance use, blood cannabinoid levels, and acute mood/drug effects before and after use of product during a mobile laboratory visit.
Top validated assessments include: AUDIT, BDI-II, MWC, MCQ, STAI, ASRS, PSS, RSRS, GAD-7, BAI, MDS, TLFB, DASS, L-CAT, DEQ, ARCI/M-Scale, Dot Probe Task, NCB, ISLT, EATS, RI, PANAS, and POMS.
Related Publications
- For an always up-to-date list of publications associated with this dataset, visit the OASIS project webpage or view publications from this study on PubMed.
Realm of Caring Observational Research Registry (ORR)
Contributed by: Realm of Caring Foundation
CataloguedDataset Summary
The Observational Research Registry (ORR) is Realm of Caring’s longitudinal, real-world registry of individuals using cannabinoid products to manage a wide range of health conditions. Participants self-report across repeated waves, providing an observational picture of who uses cannabinoids, the products and doses they use, the conditions they are managing, their concomitant medications, and validated measures of anxiety, depression, and sleep over time.
This de-identified Version 1 dataset (final data validated November 2020) comprises 1,816 respondents contributing 16,791 condition records, 12,118 medication records, 2,320 cannabis-product exposure records, and 7,661 scored instrument administrations across multiple waves. Measures include demographics (sex, race, education, state, and age); health conditions coded to ICD-10-CM and MONDO, spanning primary diagnoses, comorbidities, and rare or genetic conditions; concomitant medications coded to RxNorm and ATC with route, daily dose, and indication; cannabis exposure as the treatment variable (product brand, route, cannabinoid profile [CBD-only, CBD+THC, or THC-only], and CBD/THC milligrams per day); and validated instruments — HADS-Anxiety, HADS-Depression, PSQI, and CSHQ — with native scores, clinical bands, and a harmonized cross-instrument severity axis.
The dataset is de-identified — pseudonymous participant keys, ages 90 and older top-coded, direct identifiers redacted, and geography limited to state level. It is intended to support research on real-world cannabinoid use, therapeutic outcomes, medication substitution and adjunct use, and the health and quality-of-life impacts of medicinal cannabis.
Cannabidiol Liver Safety Clinical Trial
Contributed by: U.S. Food and Drug Administration
CataloguedDataset Summary
This dataset comes from a randomized, double-blind, placebo-controlled trial of 201 healthy adults who received either cannabidiol (CBD) at 5 mg/kg/day or placebo for 28 days.
It includes repeated measures of liver enzymes, blood counts, endocrine markers, CBD and metabolite concentrations, adverse events, and treatment adherence. The primary outcome was elevation of alanine aminotransferase or aspartate aminotransferase to more than three times the upper limit of normal.
The dataset can support research on CBD-related liver enzyme elevations, potential drug-induced liver injury, endocrine effects, pharmacokinetics, and short-term safety.
Related Publications
- Florian J, Salcedo P, Burkhart K, et al. Cannabidiol and liver enzyme level elevations in healthy adults: a randomized clinical trial. JAMA Internal Medicine. 2025;185(9):1070–1078.
CHRI aims to inform clinical decision-making, product development and public policy related to the therapeutic use of cannabinoids.